Global Cancer Supportive Care Drugs Market Report and Forecast 2023-2031
Global Cancer Supportive Care Drugs Market Outlook
The global cancer supportive care drugs market size attained a value of USD 20.7 billion in 2022. The market is anticipated to grow at a CAGR of 2.3% during the forecast period of 2023-2031 to attain a value of USD 25.3 billion by 2031.
Cancer Supportive Care Drugs Market: Introduction
Cancer supportive care drugs are a class of medications used to help manage and alleviate the side effects and symptoms associated with cancer and its treatments, such as chemotherapy, radiation therapy, and targeted therapies. These drugs aim to improve the quality of life for cancer patients, allowing them to better tolerate cancer treatments, enhancing their overall well-being, and supporting their recovery process.
Uses of cancer supportive care drugs include:
1. Managing side effects: Cancer supportive care drugs help manage side effects caused by cancer treatments, such as nausea, vomiting, pain, fatigue, and anaemia.
2. Enhancing treatment effectiveness: Some cancer supportive care drugs can be used in combination with other cancer treatments to enhance their effectiveness, minimize side effects, and improve patient outcomes.
3. Addressing complications: Cancer patients may experience complications due to the disease itself or its treatments. Supportive care drugs help manage these complications, such as infections, blood clotting disorders, or metabolic imbalances.
4. Palliative care: Cancer supportive care drugs play a crucial role in palliative care, providing relief from symptoms and improving the quality of life for patients with advanced or terminal cancer.
In summary, cancer supportive care drugs are medications that help manage and alleviate the side effects and symptoms associated with cancer and its treatments. They work by addressing various complications, enhancing treatment effectiveness, and improving the quality of life for cancer patients. These drugs play a crucial role in the comprehensive care and management of cancer patients, allowing them to better tolerate treatments and support their recovery process.
Cancer Supportive Care Drugs Market Segmentations
The market can be categorised into drug type, cancer type, distribution channel, and region.
Cancer Supportive Care Drugs Market Breakup by Drug type
- Antiemetic Drugs
- Analgesic Drugs
- Colony-stimulating Factors
- Bisphosphonates
- Anti-infective Drugs
- Anti-anemia Drugs
- Monoclonal Antibodies
- Others
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Blood cancer
- Others
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Specialty pharmacies
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Cancer Supportive Care Drugs Market Scenario
The Cancer Supportive Care Drugs Market is a rapidly growing industry that provides various medications and treatments to manage the symptoms and side effects of cancer and its treatment. Cancer is a complex disease that requires a multifaceted approach to treatment, including surgery, radiation therapy, chemotherapy, and immunotherapy. However, these treatments often come with debilitating side effects such as nausea, vomiting, pain, and fatigue, which can significantly impact the patient's quality of life.
Cancer supportive care drugs aim to alleviate these side effects and improve the overall well-being of cancer patients. These drugs include antiemetics to manage nausea and vomiting, pain medications to manage cancer-related pain, hematopoietic growth factors to stimulate the production of blood cells, and bone-targeted agents to manage bone complications associated with cancer.
The global Cancer Supportive Care Drugs Market is expected to grow significantly in the coming years, primarily due to the rising incidence of cancer worldwide. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with an estimated 10 million deaths in 2020 alone. This high prevalence of cancer has led to an increase in demand for supportive care drugs that can improve the quality of life for cancer patients.
In addition to the rising incidence of cancer, the increasing availability of advanced supportive care drugs and the development of new and innovative treatments are also driving the growth of the Cancer Supportive Care Drugs Market. Pharmaceutical companies are investing heavily in research and development to create drugs that are more effective and have fewer side effects. The market is also witnessing a trend towards personalized medicine, where treatments are tailored to the unique needs of individual patients.
In conclusion, the Cancer Supportive Care Drugs Market is a vital industry that plays a crucial role in improving the quality of life of cancer patients. The increasing prevalence of cancer and the development of new and innovative treatments are expected to drive the growth of the market in the coming years, providing hope for cancer patients worldwide.
Key Players in the Global Cancer Supportive Care Drugs Market
The report gives an in-depth analysis of the key players involved in the cancer supportive care drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- F. Hoffmann-La Roche AG
- HELSINN Healthcare SA
- Tesaro
- Novartis International AG
- Heron Therapeutics
- Merck & Co., Inc.
- Amgen Inc.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Cancer Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Cancer Epidemiology Analysis
- 5.1 Epidemiology Overview (2016-2031)
- 5.2 North America Cancer Epidemiology (2016-2031)
- 5.3 Europe Cancer Epidemiology (2016-2031)
- 5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
- 5.5 Latin America Cancer Epidemiology (2016-2031)
- 5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
- 6 Global Cancer Supportive Care Drugs Market Overview
- 6.1 Global Cancer Supportive Care Drugs Market Historical Value (2016-2022)
- 6.2 Global Cancer Supportive Care Drugs Market Forecast Value (2023-2031)
- 7 Global Cancer Supportive Care Drugs Market Landscape
- 7.1 Global Cancer Supportive Care Drugs Company Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Global Cancer Supportive Care Drugs Product Landscape
- 7.2.1 Analysis by Drug Type
- 7.2.2 Analysis by Cancer Type
- 7.2.3 Analysis by Distribution Channel
- 8 Cancer Therapeutics Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Global Cancer Supportive Care Drugs Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Global Cancer Supportive Care Drugs Market Segmentation
- 11.1 Global Cancer Supportive Care Drugs Market by Drug Type
- 11.1.1 Market Overview
- 11.1.2 Antiemetic Drugs
- 11.1.3 Analgesic Drugs
- 11.1.4 Colony-stimulating Factors
- 11.1.5 Bisphosphonates
- 11.1.6 Anti-infective Drugs
- 11.1.7 Anti-anemia Drugs
- 11.1.8 Monoclonal Antibodies
- 11.1.9 Others
- 11.2 Global Cancer Supportive Care Drugs Market by Cancer Type
- 11.2.1 Market Overview
- 11.2.2 Breast cancer
- 11.2.3 Lung cancer
- 11.2.4 Colorectal cancer
- 11.2.5 Prostate cancer
- 11.2.6 Blood cancer
- 11.2.7 Others
- 11.3 Global Cancer Supportive Care Drugs Market by Distribution Channel
- 11.3.1 Market Overview
- 11.3.2 Hospital pharmacies
- 11.3.3 Retail pharmacies
- 11.3.4 Online pharmacies
- 11.3.5 Specialty pharmacies
- 11.4 Global Cancer Supportive Care Drugs Market by Region
- 11.4.1 Market Overview
- 11.4.2 North America
- 11.4.3 Europe
- 11.4.4 Asia Pacific
- 11.4.5 Latin America
- 11.4.6 Middle East and Africa
- 12 North America Cancer Supportive Care Drugs Market
- 12.1 Market Share by Country
- 12.2 United States of America
- 12.3 Canada
- 13 Europe Cancer Supportive Care Drugs Market
- 13.1 Market Share by Country
- 13.2 United Kingdom
- 13.3 Germany
- 13.4 France
- 13.5 Italy
- 13.6 Others
- 14 Asia Pacific Cancer Supportive Care Drugs Market
- 14.1 Market Share by Country
- 14.2 China
- 14.3 Japan
- 14.4 India
- 14.5 ASEAN
- 14.6 Australia
- 14.7 Others
- 15 Latin America Cancer Supportive Care Drugs Market
- 15.1 Market Share by Country
- 15.2 Brazil
- 15.3 Argentina
- 15.4 Mexico
- 15.5 Others
- 16 Middle East and Africa Cancer Supportive Care Drugs Market
- 16.1 Market Share by Country
- 16.2 Saudi Arabia
- 16.3 United Arab Emirates
- 16.4 Nigeria
- 16.5 South Africa
- 16.6 Others
- 17 Patent Analysis
- 17.1 Analysis by Type of Patent
- 17.2 Analysis by Publication year
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Patent Age
- 17.5 Analysis by CPC Analysis
- 17.6 Analysis by Patent Valuation
- 17.7 Analysis by Key Players
- 18 Grants Analysis
- 18.1 Analysis by year
- 18.2 Analysis by Amount Awarded
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Grant Application
- 18.5 Analysis by Funding Institute
- 18.6 Analysis by NIH Departments
- 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Funding Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Regulatory Framework
- 22.1 Regulatory Overview
- 22.1.1 US FDA
- 22.1.2 EU EMA
- 22.1.3 INDIA CDSCO
- 22.1.4 JAPAN PMDA
- 22.1.5 Others
- 23 Supplier Landscape
- 23.1 F. Hoffmann-La Roche AG
- 23.1.1 Financial Analysis
- 23.1.2 Product Portfolio
- 23.1.3 Demographic Reach and Achievements
- 23.1.4 Mergers and Acquisitions
- 23.1.5 Certifications
- 23.2 HELSINN Healthcare SA
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Tesaro
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Novartis International AG
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Heron Therapeutics
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Merck & Co., Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 Amgen Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 24 Global Cancer Supportive Care Drugs Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
- 26.1 Very Small Companies
- 26.2 Small Companies
- 26.3 Mid-Sized Companies
- 26.4 Large Companies
- 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
- 27.1 Government Funded
- 27.2 Private Insurance
- 27.3 Out-of-Pocket
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook